Business Wire

Talkdesk Enters Next Decade Fueled by Innovation, Expanded International Presence, New Brand

27.4.2021 18:30:00 EEST | Business Wire | Press release

Share

Talkdesk®, Inc., the global customer experience leader for customer-obsessed companies, today embarked on the next phase of growth after two years of significant momentum in executing toward its bold vision to provide a better way for organizations to unlock the promise and potential of great customer service. To mark this new stage in its corporate maturation, Talkdesk unveiled a new logo and tagline – Experience. A better way. – that reflects the company’s commitment to being at the forefront of customer experience (CX) innovation and its focus on empowering customers to build brand trust and loyalty through customized, personal interactions.

Talkdesk’s reimagined logo reflects its commitment to helping companies connect every engagement moment into customer journeys that are personalized, productive and profitable. The bold new corporate identity comprises a fresh purple color palette and updated brand elements, featuring inclusive and diverse visual representations and illustrations that reflect the importance of human connection. The company also relaunched its website in five new languages – Brazilian Portuguese, French, German, Portuguese and Spanish, and unveiled a powerful new international advertising campaign.

“Today is about retelling the Talkdesk story in a way that pays tribute to our legacy, embraces our commitment to diversity and giving back, and deeply connects our path forward to the thousands of Talkdesk customers and employees who made what is yet to come possible,” said Kathie Johnson, chief marketing officer, Talkdesk. “Every element of who we are represents the importance of the connection we help companies make with their customers, because every moment matters.”

Talkdesk today also introduced availability of two additions to Talkdesk CX Cloud™ designed to propel the company into its new wave of growth: Talkdesk Workspace, a customizable user interface, and Talkdesk Builder, a set of tools for unlimited and accelerated contact center customization across workspaces, routing, reporting and integrations. Since its inception, rapid innovation has been a Talkdesk hallmark – one applauded by both customers and industry leaders, and valued by enterprise customers worldwide.

“Ten years ago, Talkdesk founder Tiago Paiva saw how Salesforce had re-invented the CRM world and realized a similar revolution was imminent for the call center,” said Sheila McGee-Smith, founder and principal analyst, McGee-Smith Analytics, LLC. “Talkdesk has been a significant part of the industry-wide contact center transformation, helping to move the industry toward a true elastic cloud, with all the innovation power that brings for not just customers but the entire customer experience ecosystem.”

Over the past 24 months, Talkdesk achieved several significant milestones, including:

  • An international expansion that extended the company’s footprint not only within Portugal, the United Kingdom and the United States, but also into Australia, Brazil, France, Germany, Ireland, Italy, the Netherlands, Southeast Asia and Spain
  • A proven executive leadership team – which is 45% female – with experience at some of the technology industry’s leading companies, including AT&T, Cloudera, Oracle, Salesforce and SAP
  • Bringing to market 20 innovations in the first 20 weeks of 2020, including solutions designed to help its customers through the pandemic
  • Expansion and strengthening of its partner ecosystem of cloud distributors, resellers, marketplace and strategic alliance partners
  • Launching industry specific solutions to help address the unique customer service challenges of financial services and insurance, healthcare and life sciences, retail and e-commerce, and travel and hospitality companies
  • Raising Series C funding of $143 million, bringing the company’s valuation to more than $3 billion
  • Positioned as a leader in the 2020 Gartner Cloud Contact Center as a Service (CCaaS) Magic Quadrant
  • Positioned as a leader in the 2020 Forrester Wave for CCaaS

“Today marks an inflection point in Talkdesk history. Talkdesk was founded on the principle that there had to be a better way for companies to deliver exceptional customer service. We now have customers in every major region of the world who have transformed their end-customers’ experience into an immersive, personalized and profitable journey,” said Tiago Paiva, Talkdesk founder and chief executive officer. “Our cloud-native platform was one of many industry-firsts Talkdesk introduced to the contact center marketplace over its first decade, and our talented

development team is hard at work on the products that will define our next 10 years of audacious innovation.”

Additional Resources

  • Read Kathie Johnson’s perspective on leading Talkdesk through transformation growth as the company’s first chief marketing officer
  • Read the press release introducing Talkdesk Workspace, a customizable interface designed to enable a better way to deliver superior customer experiences in contact centers
  • Learn more about the new Talkdesk brand

Social Networks

About Talkdesk

Talkdesk® is a global customer experience leader for customer-obsessed companies. Our contact center solution provides a better way for businesses and customers to engage with one another. Our speed of innovation and global footprint reflect our commitment to ensure businesses everywhere can deliver better customer experiences through any channel, resulting in higher customer satisfaction, cost savings and profitability. Talkdesk CX CloudTM is an end-to-end customer experience solution that combines enterprise scale with consumer simplicity. Over 1,800 innovative companies around the world, including IBM, Acxiom, Trivago, and Fujitsu partner with Talkdesk to deliver a better way to great customer experience. Learn more and request a demo at www.talkdesk.com.

Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks ™ or registered ® trademarks of their respective holders. Use of the does not imply any affiliation or endorsement by them.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:
Americas
Camille Beasley
camille.beasley@talkdesk.com
(972) 896-1936

EMEA
Douglas Keighley
douglas.keighley@talkdesk.com
+44 7830144613

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye